News Release

Suven Life Sciences’ ACT Enters into an Alliance with VPSCRO

Hyderabad, India April 8, 2008 - Suven Life Sciences Limited announced today that its clinical research division Asian Clinical Trials (ACT) has entered into a strategic alliance with  VPSCRO, a CRO based in Beijing, China to conduct clinical trial services in India, as well as in China.

This strategic alliance between ACT and VPSCRO will allow us to offer comprehensive range of clinical services to global sponsors with the state of the art infrastructure, network of trained investigators in India and China by leveraging their expertise for the conduct of quality clinical research.

Dr. Charlie Xu, M.D., Director, Global Business Development of VPSCRO said "We are excited to start our collaboration with ACT, a Division of Suven Life Science Limited. Together we will partner to build a world class CRO platform to conduct clinical trials in Asia Region”

“Given the fact that 50% of global population living in India and China and the global pharmaceutical industry’s ever increasing demand to reachout diversified patient population, the strategic collaboration between ACT and VPSCRO provide with a platform offering full-fledged clinical research solutions in Asian region to global sponsors. Such collaboration aims at providing high quality, cost effective clinical research services with greater speed in patient recruitment from the region” said Venkatraman Sunder, Vice President, Operations for ACT.

 “We are very enthusiastic with the many opportunities to make this alliance a success not only for ACT and VPSCRO, but also to our global sponsors around the world” says Mr Venkat Jasti, CEO of Suven Life Sciences.

About Suven Life Sciences

Suven Life Sciences is a biopharmaceutical company focused on the drug discovery, development of orally active drugs to address significant unmet medical needs with a primary focus on the treatment of debilitating CNS disorders such as Alzheimer’s disease, schizophrenia, depression, vascular dementia, mild cognitive impairment, Parkinson’s disease, memory impairments with aging, sleep disorders, feeding disorders and obesity. In addition, leading global pharma access our drug discovery capabilities and expertise through collaborations to design, create, optimize and evaluate drug candidates across a wide range of therapeutic areas. For more info on Suven please log onto www.suven.com.

Asian Clinical Trials (ACT) is a CRO division of Suven Life Sciences Limited, providing complete solutions for global pharmaceutical, biotechnology and medical device companies in clinical research. ACT aims to maximize customer value by providing high quality, cost effective, professionalized services. ACT data management solutions are supported by fully validated technology platform like latest version of Oracle Clinical 4.5. The team comprises of a complementary group of professionals representing the fields of Medicine, Nursing, Pharmacology, Microbiology, Toxicology, Statistics, Software Engineering, Business, and Law. Collectively they contribute over 60 years of experience in the drug discovery and clinical development arena, gained in the US, UK, and India. Our team in New Jersey and North Carolina in USA provides seamless project management and customer support with backend operations in Hyderabad, India. For more information on ACT, please log onto www.act-india.com.
 

About Venturepharm & VPSCRO

Venturepharm group is an Asia based, life science leader with principal activities in an innovative full service plus model from venture capital, merchant banking, CRO, CMO, CSO, compound partnering to royalty sharing. Venturepharm engages in strategic licensing of therapeutic compound pipelines, and markets projects to China, an emerging global top five market. Two of the flagships from the group are public trade companies:

Venturepharm Lab (HK stock exchange 8225)

Commonwealth Biotechnologies, Inc (NASDAQ: “CBTE”)

For more info about Venturepharm, please visit  www.venturepharm.com.

VPSCRO is the No.1 CRO in China for global specialty pharma and Biotech Company. VPSCRO’s expertise covers both clinical trial and pre-clinical studies. VPSCRO is also the largest Chinese CRO in term of numbers of on going trials. VPSCRO has extensive experience in the therapeutic areas of Oncology, CV, CNS and HIV. VPSCRO is also a national leader in data management, phase IV studies, and clinical marketing service. VPSCRO was rated as The 2002 Top Ten Management Company in China. The group won the 2007 Frost & Sullivan Award - Best CRO in Asia. For more info on VPSCRO please log onto www.vpscro.com

Honors: